The following full text is a publisher’s version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/172307

Please be advised that this information was generated on 2019-02-17 and may be subject to change.
Diagnosis and treatment based on quantitative PCR after controlled human malaria infection

Jona Walk¹, Remko Schats²†, Marijke C. C. Langenberg², Isaie J. Reuling¹, Karina Teelen¹, Meta Roestenberg¹, Cornelus C. Hermsen¹, Leo G. Visser² and Robert W. Sauerwein¹*

Abstract

Background: Controlled human malaria infection (CHMI) has become well-established in the evaluation of drugs and vaccines. Anti-malarial treatment is usually initiated when thick blood smears are positive by microscopy. This study explores the effects of using the more sensitive qPCR as the primary diagnostic test.

Methods: 1691 diagnostic blood samples were analysed by microscopy and qPCR from 115 volunteers (55 malaria naïve and 60 having received chemoprophylaxis and sporozoite immunization) who were challenged by five mosquitoes infected with Plasmodium falciparum sporozoites of the NF54 strain.

Results: Retrospective analysis of different qPCR criteria for diagnosis and treatment, showed that once daily qPCR (threshold 100 parasites/ml) had 99 % sensitivity and 100 % specificity, and shortened the median prepatent period from 10.5 to 7.0 days after CHMI when compared to twice daily measurement of thick blood smears (threshold 4000 parasites/ml). This is expected to result in a 78 % decrease of adverse events before initiation of treatment in future studies. Trial outcome related to infection and protective efficacy remained unchanged.

Conclusion: The use of qPCR as the primary diagnostic test in CHMI decreases symptoms as well as parasitaemia while obviating the need for twice daily follow-up. The implementation improves safety while reducing the clinical burden and costs without compromising the evaluation of protective efficacy.

Keywords: Malaria, Plasmodium falciparum, Controlled human malaria infection (CHMI), quantitative PCR (qPCR)
(LUMC). Despite an acceptable safety profile, CHMIs inevitably cause mild to moderate malaria symptoms such as headache, myalgia and malaise in almost all volunteers, and severe (grade 3) symptoms in about half of volunteers [3, 6]. Moreover, there have been three serious adverse cardiac events shortly after treatment for parasitaemia that have remained incompletely understood [7, 8]. As clinical malaria symptoms are only associated with asexual blood stages, a shorter duration of parasitaemia may reduce the number and severity of adverse events, thereby further minimizing risks and volunteer burden. In addition, treating volunteers before (severe) symptoms occur, would simplify the conduct and follow-up, thereby lowering costs.

In this retrospective study, different thresholds for qPCR diagnostics were analyzed in relation to prepatent period and occurrence of adverse events as well as effects on assessment of protective efficacy.

**Methods**

**Study volunteers**

Retrospective qPCR data that had previously been generated were collected from nine CHMI trials performed at the Radboud university medical center (Radboudumc), the ‘Harbour Hospital’ in Rotterdam or the Leiden University Medical Centre (LUMC) between 2007 and 2012 [9–15], Table 1.

All study subjects were healthy female and male volunteers between the age of 18 and 35 years exposed to bites of five *Plasmodium falciparum* NF54 strain infected *Anopheles stephensi* mosquitoes. Prior to challenge infection, 55 volunteers were malaria naïve and 60 had received chemoprophylaxis and sporozoite (CPS) immunization. CPS-immunization was administered via infected mosquito bites at different dosages under chloroquine or mefloquine prophylaxis, as described previously [10–14].

Prior to inclusion, study volunteers were medically screened as described previously [13] and provided written informed consent. All clinical trials were approved by the Radboudumc Committee on Research Involving Human Subjects (CMO) or the Central Committee on Research Involving Human Subjects (CCMO) of the Netherlands.

**Parasitological data**

Treatment was initiated after CHMI when a thick blood smear was found positive for parasites. Thick smears were made twice or three times daily and read according to a standard protocol [11]. In short, a slide was considered positive if after reading the number of fields equivalent to 0.5 μL of blood at least two parasites were seen (a threshold of four parasites per μL), and positivity was confirmed by a second independent reader. qPCR

| Table 1 Summary of data included in the analysis |
|------------------------------------------------|
| **Year** | **Number of volunteers** | **CPS-immunization** | **Patent parasitemia** | **Pre-patent period** | **References** |
|---------|-------------------------|----------------------|-----------------------|----------------------|----------------|
|         |                         |                      |                       | **Median** | **Range** |             |
| Study 1 | 2007                    | 10                   | 3 × 12–15 mosquitoes  | 0/10      | –        | –          | Roestenberg et al. [13] |
|         |                         | 5                    | –                     | 5/5       | 9        | 7–10.5     |             |
| Study 2 | 2007                    | 18                   | –                     | 18/18     | 10.5     | 9–12.5     | Roestenberg et al. [14] |
| Study 3 | 2009                    | 6                    | 3 × 12–15 mosquitoes  | 2/6       | 16.8     | 15–18.6    | Teirlinck et al. [15] |
|         |                         | 4                    | –                     | 4/4       | 8.5      | 7.5–10.5   |             |
| Study 4 | 2010                    | 5                    | –                     | 4/5       | 10.6     | 10.6–11    |             |
| Study 5 | 2011                    | 5                    | 3 × 15 mosquitoes     | 1/5       | 12       | –          | Bijker et al. [12] |
|         |                         | 9                    | 3 × 10 mosquitoes     | 1/9       | 12       | –          |             |
|         |                         | 10                   | 3 × 5 mosquitoes      | 5/10      | 11       | 9–15       |             |
|         |                         | 5                    | –                     | 5/5       | 9.5      | 9–13.5     |             |
| Study 6 | 2011                    | 5                    | 3 × 15 mosquitoes     | 0/5       | –        | –          | Bijker et al. [10] |
|         |                         | 5                    | –                     | 5/5       | 12.5     | 9.5–12.5   |             |
| Study 7 | 2012                    | 15                   | 3 × 8 mosquitoes      | 5/15      | 12       | 11–14      | Bijker et al. [11] |
|         |                         | 4                    | –                     | 4/4       | 8.5      | 7–12       |             |
| Study 8 | 2012                    | 5                    | –                     | 5/5       | 10.5     | 9–10.5     |             |
| Study 9 | 2012                    | 5                    | –                     | 5/5       | 12       | 10.5–16    | Bastiaens et al. [9] |

Data was included from all malaria naïve or CPS-immunized volunteers undergoing challenge infection with bites from five mosquitoes infected NF54 since 2007

* Only volunteers with patent parasitemia included. In all studies pre-patent period is defined as time to positive thick blood smear

* Volunteers received three immunization with a candidate malaria vaccine but were unprotected from challenge infection

* Rechallenge of CPS-immunized volunteers from Study 1, 2.5 years after immunization and malaria naïve controls
assessment was performed according to previously published protocols [16]. qPCR was performed retrospectively from samples taken twice per day from day 5 until day 15 after challenge and once per day from day 16 until day 21.

Recording of adverse events
Subjects were asked to keep a diary recording symptoms while followed up for adverse events (AEs) on an outpatient basis once or twice daily starting on day 5 after challenge infection until day 21. Adverse events were collected until end of study visits either on day 28 or day 35 after challenge, depending on the study. An adverse event was defined as any undesirable symptom occurring after challenge infection. AEs were defined as grade 1, no interference with daily activity; grade 2, some interference with daily activity; or grade 3, requiring bed rest. The following symptoms were solicited: fever, headache, malaise, fatigue, myalgia, arthralgia, nausea, vomiting, chills, diarrhoea and abdominal pain.

Statistical analysis
Depending on the study, qPCR data was analysed using Microsoft Excel (version 2007) for Windows or using a specialized electronic Case Report Form program (Hermsen Computer Services) created for Radboudumc CHMI trials. Data was combined using Microsoft Excel 2007 for Windows and statistical analysis was performed using IBM SPSS Statistics 22 for Windows.

Results
Fifty-five malaria naïve volunteers in nine trials received a challenge infection with bites from five NF54 infected mosquitoes. Geometric mean parasitaemia curves generated from retrospective qPCR data were similar between trials, Fig. 1a. These volunteers received anti-malarial treatment at positive thick blood smear at a median of 10.5 days post-challenge (range 7.0–16.0). Based on the retrospective qPCR data, initiating treatment based on qPCR can gradually decrease the duration of parasitaemia, depending on the treatment threshold and blood sampling frequency used, Fig. 1b. When two consecutive positive qPCR measurements above 500 parasites/ml are used as a criterion to initiate treatment, volunteers are treated at a median of 9 days post CHMI. When only a single positive qPCR is required to initiate treatment, the mean day of treatment decreases further. Using the threshold of 100 parasites/ml blood, the median duration of parasitaemia would decrease by 3.5 days.

All solicited adverse events that were possibly, probably or definitively related to the CHMI occurring between day 5 post-infection and the end of the study were collected. Fifty-five percent of all adverse events and 39% of severe adverse events occurred prior to the initiation of anti-malarial treatment (Fig. 1c). Importantly, only 22% of the total adverse events and 13% of grade 3 adverse events before treatment occurred before parasitaemia reached 100 parasites/ml (Fig. 1d).

Once daily blood sampling for qPCR (threshold of 100 parasites/ml), instead of twice daily sampling, did not influence the median treatment day, Fig. 1b. Five volunteers (9%) would have been treated 24 h earlier when sampling for qPCR twice daily. However, the mean number of adverse events before treatment increased only minimally when once daily sampling was used, Fig. 1d.

CPS immunization induces dose-dependent protection against CHMI [12]. Partial protection was determined by time to parasitaemia and mean parasite density of the first wave, as estimation of the liver parasite load [4]. Since both parameters depend on the method of parasite detection and treatment threshold used, it was retrospectively assessed whether the proportion of volunteers with partial protection changed with qPCR sampling once daily and initiation of treatment based on a single qPCR above 100 parasites/ml. Table 2 shows that differences in pre-patent period and mean parasitaemia of the first wave for ten partially protected volunteers and controls [11, 12] gave similar outcomes when using microscopy or qPCR.

A tentative diagnostic replacement of microscopy by qPCR requires a reliable test outcome. A total of 778 retrospective qPCR tests have been performed in 35 fully protected volunteers without a single qPCR above 100 parasites/ml. In the same studies, performed between 2010 and 2012, 107 qPCR standard curves were generated using serial dilutions of blood samples with known parasite densities, diluted from isolated ring stages whose concentration had been determined by microscopy. At densities of 20, 50 and 100 parasites/ml, the parasitaemia in these samples was correctly quantified (less than 5% deviation between duplo samples) in 63% (57/107), 87% (93/107) and 96% (103/107) of the samples, respectively. With recent introduction of a new standardized reagents mix for the DNA extraction in 2014 (MagNA Pure LC Total Nucleic Acid Isolation Kit, Roche Diagnostics), 81 of 82 standard curve samples with 100 parasites/ml and 79 of 82 samples with 50 parasites/ml were correctly measured. The combined data indicate that qPCR with threshold of 100 parasites/ml can be reliably used for diagnosis in the CHMI model, with a sensitivity of 99% and a specificity of 100%.

Discussion
This retrospective qPCR analysis shows that the duration of blood stage parasitaemia in CHMI volunteers can be shortened by 3.5 days compared to thick blood smear if
a treatment threshold of 100 parasites/ml is used. This threshold has a sensitivity of 99% and a specificity of 100%.

Shortening the duration of parasitaemia in volunteers after CHMI has several potential advantages. Most importantly, an increase in safety as malaria symptoms are related to the height and duration of parasitaemia, and the potential to greatly decrease the burden for volunteers. Over half the adverse events after CHMI occur prior to thick smear positivity. This analysis shows that anti-malarial treatment of volunteers when parasitaemia reaches 100 parasites/ml will lead to a 78% reduction in the number of adverse events occurring before treatment. Presumably, treatment of volunteers at lower parasitaemia will also lead to a decrease in adverse events occurring after treatment.

If prospective qPCR diagnostics are introduced with a low threshold (100 parasites/ml), once daily blood sampling will suffice without the need for a second sample within 24 h, as there appears to be only a slight effect on the duration of parasitaemia and/or the number of adverse events. Five volunteers (9%) would have been treated 24 h earlier when sampling for qPCR twice daily. Notwithstanding, we still favour once daily sampling considering the great burden of twice-daily blood sampling and the absence of a significant increase in the number of AEs at that very low parasitaemia. Shortening the duration of parasitaemia and decreasing the frequency
of blood sampling will significantly reduce the follow-up of CHMI volunteers. Given the intensive visit schedule for volunteers, requiring multiple personnel and safety laboratory evaluations, the reduced follow-up period will substantially simplify the conduct of these trials, which will also lower CHMI costs. However, these benefits should not compromise the scientific value of the trial. This study shows that using these diagnostic criteria will not impede the ability to discriminate the delay in parasitaemia and/or reduction in mean first wave parasitaemia as proxy for parasite liver stage development that occurs when a vaccine provides partial pre-erythrocytic protection. Therefore, using once daily qPCR with 100 parasites/ml threshold will likely provide a similar primary outcome of protective vaccine efficacy in prospective studies. However, the standard deviations of both mean time to parasitaemia and mean first wave parasitaemia in the vaccination groups increased in this analysis. Consequently, when a relatively smaller difference is anticipated between vaccinees and controls, use of these qPCR criteria may require an increase in sample size to obtain sufficient statistical power.

Evaluation of qPCR data from 35 CPS-immunized and protected volunteers shows that since the introduction of the current qPCR method at Radboudumc, LUMC and the Harbour Hospital in 2010, no immunized and fully protected volunteers developed a positive qPCR after challenge above 100 parasites/ml. Therefore, using once daily qPCR with 100 parasites/ml threshold will likely provide a similar primary outcome of protective vaccine efficacy in prospective studies. However, the standard deviations of both mean time to parasitaemia and mean first wave parasitaemia in the vaccination groups increased in this analysis. Consequently, when a relatively smaller difference is anticipated between vaccinees and controls, use of these qPCR criteria may require an increase in sample size to obtain sufficient statistical power.

Evaluation of qPCR data from 35 CPS-immunized and protected volunteers shows that since the introduction of the current qPCR method at Radboudumc, LUMC and the Harbour Hospital in 2010, no immunized and fully protected volunteers developed a positive qPCR after challenge above 100 parasites/ml. Therefore, using once daily qPCR with 100 parasites/ml threshold will likely provide a similar primary outcome of protective vaccine efficacy in prospective studies. However, the standard deviations of both mean time to parasitaemia and mean first wave parasitaemia in the vaccination groups increased in this analysis. Consequently, when a relatively smaller difference is anticipated between vaccinees and controls, use of these qPCR criteria may require an increase in sample size to obtain sufficient statistical power.

### Table 2 Partial protection after CPS immunization as detected by thick smear or retrospective qPCR

|               | Number | Pre-patent period (days) | Parasitemia 1st peak (log) |
|---------------|--------|--------------------------|----------------------------|
|               |        | Mean | SD  | P value | Mean | SD  | P value |
| Positive thick smear\(^a\) |        |     |     |         |     |     |         |
| CPS-immunized (partially protected)\(^b\) | 10     | 12.2 | 1.85 | 0.006   | 1.00 | 0.56 | 0.02    |
| Controls (unprotected)     | 9      | 9.7  | 2.05 | 2.07    | 1.07 |
| Positive qPCR\(^c\) |        |     |     |         |     |     |         |
| CPS-immunized (partially protected)\(^b\) | 10     | 9.6  | 2.06 | 0.035   | 1.10 | 0.67 | 0.04    |
| Controls (unprotected)     | 9      | 7.9  | 1.83 | 1.99    | 1.06 |

Differences between mean pre-patent periods were determined by Mann–Whitney U test in ten partially protected and nine control volunteers after CPS immunization\([11, 12]\). Parasitaemia of the first parasite wave was estimated by determining the geometric mean parasitaemia from 6.5 to 8.0 days after challenge. Differences in the mean parasitaemia of the first peak was determined by an independent samples \(t\) test.

\(^a\) Threshold of 4000 parasites/ml and twice daily blood sampling
\(^b\) Only volunteers with patent parasitemia included in the analysis
\(^c\) Threshold of 100 parasites/ml and once daily blood sampling

Andrews et al.\([17]\) first demonstrated the increased sensitivity of qPCR compared to thick smear, and recognized that qPCR could be used to initiate earlier treatment, at a threshold of 1000 parasites/ml\([17]\). However, recent advances in qPCR methodology, such as the use of an automated system for extraction, has improved sensitivity at low parasite densities. The current analysis shows that this has made it possible to lower the treatment threshold much further. Likewise, other CHMI study centres have also repeatedly shown that qPCR first becomes positive 2–4 days before thick blood smear when both are determined\([18–21]\). Similarly, studies assessing blood stage drugs or vaccines have already begun to use qPCR as a primary outcome, and have confirmed its sensitivity and specificity\([22]\). In 2014 Kamau et al. analysed parasitological data from 16 subjects undergoing CHMI in two trials. They also showed that qPCR is positive 2–7 days before thick smear\([23]\). Based on their analysis, the authors recommend treatment after CHMI after two (not necessarily consecutive) positive qPCRs of which one is above 2000 parasites/ml. This threshold was chosen to assess parasite multiplication rates requiring at least two replication cycles.
For evaluation of pre-erythrocytic vaccines, however, a treatment threshold of 100 parasites/ml will be sufficiently adequate. This analysis shows that different qPCR thresholds can be chosen to assess the duration of parasitemia. For example, using two consecutive positive qPCRs above 500 parasites/ml as a threshold, prolongs the median pre-patent period to 9 days. Different qPCR treatment thresholds will therefore lead to different durations of parasitemia. In this way, CHMI can be made a fit-for-purpose model matching the diagnostic qPCR protocol with the considered primary endpoints.

Although retrospective analyses should be interpreted prudently in general, the predictive value of this study can likely be met with confidence since retrospective qPCR data have been remarkably consistent over time between CHMI trials, and CHMI centres [3]. Therefore, PCR may be preferred for diagnosis and treatment when evaluating the protective efficacy of pre-erythrocytic vaccines [19].

**Conclusions**

After CHMI, qPCR becomes positive on average 3.5 days before thick blood smear. This analysis shows that depending on the threshold used, treatment based on qPCR diagnostics can greatly reduce the pre-patent period and the number of AEs occurring before treatment. Furthermore, these data demonstrate for the first time that qPCR has sufficient sensitivity and specificity to use 100 parasite/ml as a treatment threshold without affecting trial outcome related to infection and pre-erythrocytic protective efficacy. Therefore, the implementation of these diagnostics would improve safety while reducing the clinical burden and costs without compromising the evaluation of protective efficacy.

**Abbreviations**

CHMI: controlled human malaria infection; CPS: chemoprophylaxis and sporozoite immunization; qPCR: quantitative polymerase chain reaction; CMO: Radboudumc Committee on Research Involving Human Subjects; CCMO: Central Committee on Research Involving Human Subjects of The Netherlands; AEs: adverse events.

**Authors’ contributions**

JW, RS, MR, CCH, LV and RWS conceived the study. All authors participated in the data analysis and writing of the manuscript. All authors read and approved the final manuscript.

**Author details**

1. Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud university medical center, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
2. Department of Infectious Diseases, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.

**Acknowledgements**

We would like to thank Geert-Jan van Gemert, Marga van de Vegte-Bolmer, Rianne Siebelink-Stoter, Wouter Graumans and Theo Arens for their continuing support of the controlled human malaria infection studies at the Radboud university medical center. We thank all the clinical staff who performed the controlled human malaria infection trials, Matthew McCall, An-Emmie Nieman, Else Bijker, Guido Bastiaens, Maurits van Meer, Linda Wammes, Andre van der Ven, Quirijn de Mast, Perry van Genderen, Jaap van Hellemond, Jorien Wiersma and the entire staff of the Clinical Research Center Nijmegen and the Department of Medical Microbiology of the LUMC. We thank Anja Scholzen for her advice and input in the data analysis.

**Competing interests**

The authors declare that they have no competing interests.

**Ethics approval and consent to participate**

All clinical trials were approved by the Radboudumc Committee on Research Involving Human Subjects (CMO) or the Central Committee on Research Involving Human Subjects (CCMO) of The Netherlands. Prior to inclusion, study volunteers provided written informed consent.

**Funding**

JW, IR, KT and CCH receive grant support from the Bill and Melinda Gates Foundation [Grant ID: OPP1091355; OPP1080385]. RS received grant support from The Netherlands Organisation for Health Research and Development (ZonMw) [Project 95110086].

**Received:** 8 April 2016  **Accepted:** 8 July 2016

**Published online:** 05 August 2016

**References**

1. Laurens MB, Duncan CJ, Epstein JE, Hill AV, Kornisar JL, Lyke KE, et al. A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine. 2012;30:302–4.

2. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2011;11:57–64.

3. Roestenberg M, O’Hara GA, Duncan CJ, Epstein JE, Edwards NJ, Scholzen A, et al. Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS ONE. 2012;7:e38434.

4. Hermsen CC, de Vlas SJ, van Gemert GJ, Telg D, Verhage DF, Sauerwein RW. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg. 2004;71:196–201.

5. Hermsen CC, Telg D, Linders EH, van de Locht LA, Eling WM, Mensink EJ, et al. Detection of *Plasmodium falciparum* malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol. 2001;118:247–51.

6. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries L, et al. Clinical manifestations of *Plasmodium falciparum* malaria experimentally induced by mosquito challenge. J Infect Dis. 1997;175:915–20.

7. Nieman AE, de Mast Q, Roestenberg M, Wiersma J, Pop G, Stalenhoef A, et al. Cardiac complication after experimental human malaria infection: a case report. Malar J. 2009;8:277.

8. van Meer MP, Bastiaens GJ, Boulakia M, de Mast Q, Gunasekara A, Hoffman SL, et al. Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report. Malar J. 2014;13:38.

9. Bastiaens GJ, van Meer MP, Scholzen A, Obiero JM, Vananshenassan M, van Grinsven T, et al. Safety, immunogenicity, and protective efficacy of intra-dermal immunization with aseptic, purified, cryopreserved *Plasmodium falciparum* sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial. Am J Trop Med Hyg. 2016;94:663–73.

10. Bijker EM, Bastiaens GJ, Terlincx AC, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci. 2013;110:7862–7.

11. Bijker EM, Schats R, Obiero JM, Behet MC, van Gemert GJ, van de Vegte-Bolmer M, et al. Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial. PLoS ONE. 2014;9:e112910.

12. Bijker EM, Terlincx AC, Schats R, van Gemert GJ, van de Vegte-Bolmer M, van Leshout L, et al. Cytotoxic markers associate with protection against malaria in human volunteers immunized with *Plasmodium falciparum* sporozoites. J Infect Dis. 2014;210:1605–15.
13. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009;361:468–77.
14. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet. 2011;377:1770–6.
15. Teirlinck AC, Roestenberg M, van de Vege-Bolmer M, Scholzen A, Heinrichs MJ, Siebelink-Stoter R, et al. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis. 2013;207:656–60.
16. Schats R, Bijker EM, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, van Lieshout L, et al. Heterologous protection against malaria after immunization with Plasmodium falciparum sporozoites. PLoS ONE. 2015;10:e0124243.
17. Andrews L, Andersen RF, Webster D, Dunachie S, Walther RM, Bejon P, et al. Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg. 2005;73:191–8.
18. Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Ramping T, Anagnostou NA, et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis. 2015;211:1076–86.
19. Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, et al. Protection against malaria at 1 year and immune correlates following PSpZ vaccination. Nat Med. 2016;22:614–23.
20. Murphy SC, Prentice JL, Williamson K, Wallis CK, Fang FC, Fried M, et al. Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials. Am J Trop Med Hyg. 2012;86:383–94.
21. Talley AK, Healy SA, Finney OC, Murphy SC, Kublin J, Salas CJ, et al. Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naive subjects at a new facility for sporozoite challenge. PLoS ONE. 2014;9:e109654.
22. Marquart L, Baker M, O’Rourke P, McCarthy JS. Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR. Antimicrob Agents Chemother. 2015;59:4249–59.
23. Kamau E, Alemayehu S, Feghali KC, Komisar J, Regules J, Cowden J, et al. Measurement of parasitological data by quantitative real-time PCR from controlled human malaria infection trials at the Walter Reed Army Institute of Research. Malar J. 2014;13:288.